Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $350 from $348 and keeps a Buy rating on the shares. The firm, which is updating its model to reflect Q1 results, maintains its “positive conviction” on what it identifies as its top Midcap Biotech stock pick.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue